Medicenna Therapeutics Income Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Year	2022	2021	2020	2019	2018
Selling, General & Admin	7	7.76	6.53	2.38	1.71
Research & Development	9.3	14.72	10.87	5.87	3.02
Operating Expenses	16.3	22.47	17.4	8.25	4.73
Operating Income	-16.3	-22.47	-17.4	-8.25	-4.73
Other Expense / Income	-6.26	0.1	-0.11	0.03	-0.02
Pretax Income	-10.05	-22.58	-17.29	-8.28	-4.71
Net Income	-10.05	-22.58	-17.29	-8.28	-4.71
Shares Outstanding (Basic)	65	54	50	32	26
Shares Outstanding (Diluted)	65	54	50	32	26
Shares Change	19.25%	9.31%	55.68%	24.25%	-
EPS (Basic)	-0.16	-0.42	-0.35	-0.26	-0.18
EPS (Diluted)	-0.16	-0.42	-0.35	-0.26	-0.18
Free Cash Flow	-12.66	-23.58	-15.31	-5.42	-8.39
Free Cash Flow Per Share	-0.20	-0.43	-0.31	-0.17	-0.33
EBITDA	-10.04	-22.54	-17.25	-8.27	-4.7
Depreciation & Amortization	0	0.04	0.04	0.01	0.01
EBIT	-10.05	-22.58	-17.29	-8.28	-4.71

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).